CD163 Targeting Theranostic Agent for Macrophage Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecular imaging agents lack the ability to accurately and non-invasively target CD163+ macrophages, which are crucial for diagnosing and managing atherosclerotic plaque vulnerability and inflammation, due to the absence of specific molecular agents for CD163 targeting.
Innovation Solution
Development of a CD163 targeting and theranostic composition comprising a targeting peptide, a chelator, and a theranostic agent, such as 64Cu, which is administered to detect CD163+ macrophages, allowing for the imaging and potential treatment of atherosclerotic plaques and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If molecular imaging agents are developed to detect macrophage biomarkers (CCR2, CXCR4), then the ability to assess atherosclerotic lesion vulnerability is improved, but the ability to accurately predict plaque rupture and track resident macrophages is insufficient
Solution Approach 1:
The patent transitions from detecting chemokine receptors (CCR2, CXCR4) to detecting CD163, a fundamentally different biomarker parameter that is exclusively expressed by resident macrophages. This parameter change enables accurate tracking of resident macrophage populations and their temporal-spatial distribution, thereby improving the reliability of plaque rupture prediction while maintaining detection precision through specific molecular targeting.
Solution Approach 2:
The patent creates a molecular copy/targeting agent specifically designed for CD163 that mirrors the exclusive expression pattern of resident macrophages. This copying approach allows the imaging agent to faithfully reproduce and visualize the distribution of resident macrophages in vivo, enabling accurate assessment of plaque vulnerability and predictive capability for rupture events.
2Loss of information
If CD163 targeting agents are developed for resident macrophage detection, then the ability to track temporal-spatial distribution of macrophages is improved, but the complexity of developing specific molecular agents increases
Solution Approach 1:
The patent extracts and isolates the CD163 targeting function from complex macrophage detection systems. By focusing exclusively on CD163 as the target antigen and developing dedicated imaging agents (such as radiolabeled antibodies or small molecules) that specifically bind to CD163, the patent simplifies the detection system while capturing the essential temporal-spatial distribution information of resident macrophages across multiple organs.
Solution Approach 2:
The patent develops CD163 targeting agents with multi-functional capabilities that can track resident macrophages across diverse tissues and disease states. These universal agents maintain consistent performance in detecting CD163+ macrophages in different organs (liver, brain, atherosclerotic plaques) and at different time points, thereby reducing the need for organ-specific or disease-specific agent development while preserving comprehensive temporal-spatial information.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables non-invasive detection and monitoring of CD163+ macrophages, providing insights into atherosclerotic plaque vulnerability and inflammation, potentially guiding immunomodulatory therapies and improving treatment outcomes.
Implementation Method 1
a chelator and a theranostic agent
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of compositions of CD163 targeting and theranostic agents and methods for use in detecting, monitoring, and evaluating CD163 associated diseases, disorders, and conditions.